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Background
In the last decades the incidence of peptic ulcer disease
(PUD) has increased especially in the elderly. Haemor-
rhage is the most frequent PUD complication and its inci-
dence is increasing in comparison to perforation and
stenosis. Therapeutic endoscopy is considered the treat-
ment of choice for bleeding ulcers, reducing the need for
emergent surgical procedures to 10–20% of the cases.
Patients and methods
This retrospective study investigates a consecutive series of
98 patients, hospitalized for bleeding peptic ulcer, within
7 years, in General Surgery Unit, University of Trieste. The
incidence was slightly higher in the males (53 males and
45 females), with a median age of 68.64 years (range: 17–
99). 30 patients were <65 years, 25 between 65 and 74
years, 27 between 75 and 84 years and 16 >84 years.
The position of the ulcer resulted duodenal or pre-pyloric
in the majority of the cases, without any statistically sig-
nificant difference in the various age groups (Pearson Chi-
Square (p) < 0.492). Sixty patients presented with co-mor-
bidities: cardiovascular in 28 cases, arterial high blood
pressure in 20, respiratory in 11, neurological in 6, hae-
patic in 3, renal in 2, diabetes in 8, rheumatoid arthritis in
2, tumors in 5 and recent surgical procedure of inguinal
hernio-plastic in 1. In 28 cases there was only one con-
comitant pathology, in 19 cases 2 and in 13 cases more
than 2.
The management of these patients starts with a diagnostic
esophago-gastro-duodenalscopy (EGDS), followed by
endoscopic therapy in case of active haemorrhage.
Patients without active bleeding are treated medically
with proton pomp inhibitors and with Helicobacter pylori
eradicative treatment, if present. In the event of re-bleed-
ing a new EGDS is required with further endoscopic hae-
mostasis in the presence of active bleeding. Suspicion of
bleeding is based on melena or hematemesis or a progres-
sive decrease of the hematocritus. Patients judged techni-
cally ineligible for further endoscopic haemostasis, are
treated with emergent surgery.
In the case series, EGDS was performed in 96 out of 98
patients because 1 patient refused any medical procedure
and 1 underwent an emergency operation for haemor-
rhagic shock. In 36 cases, the EGDS failed to show any
sign of active bleeding, whereas in 60 cases bleeding was
present and haemostasis was performed. Of these 60 cases
with active bleeding, 17 were <65 years, 16 were between
65 and 74 years, 14 were between 75 and 84 years and 13
were >84 years (p = 0.478).
The study evaluated the incidence of re-bleeding and the
type of treatment used, the mortality and the complica-
tions in the different age groups in relation to the type of
treatment and the correlation between the number of
endoscopic haemostasis and mortality.
The statistical analysis, univariate and multivariate, was
performed with SPSS. Multivariate analysis aimed at esti-
mating the role of age, ulcer's position, ASA score, type of
treatment, number of transfusions and number of EGDSs
on hospital mortality and morbidity was performed with
the use of the blocks model.
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Of the 60 patients with active bleeding, 40 (66.6%) had
their haemorrhage resolved with the first endoscopic
treatment. Their ages were: 12 <65 years, 10 between 65
and 74 years, 12 between 75 and 84 years and 6 >84 years.
As for the 20 patients with re-bleeding, 17 were submitted
to a new endoscopic haemostasis and 3 to surgical proce-
dures. Of these 17 treated with a new endoscopic haemos-
tasis, 7 were <65 years, 4 between 65 and 74 years, 5
between 75 and 84 years and 4 >84 years. The second
endoscopic therapy resolved bleeding in 4 additional
cases (25.6%). The remaining 13 patients experienced
additional bleeding and were treated in 9 cases with a
third endoscopic haemostasis and in 4 cases with surgery.
The third endoscopic treatment, resolved bleeding in 2
additional cases. The remaining 7 patients experienced
additional bleeding and were treated in 3 cases with a
fourth endoscopy and in 4 cases with surgery. Only 1 out
of the 3 cases treated endoscopically achieved the resolu-
tion of the hemorrhage whereas the 2 with persistent
bleeding were treated in 1 case with a fifth endoscopic
haemostasis and in 1 case with surgery. The failure of the
fifth endoscopic haemostasis required surgical interven-
tion. In conclusion, medical and endoscopic treatment,
even when repeated, resolved hemorrhage in 47 out of 60
cases (78.3%). Of these 47 cases, 15 were <65 years, 12
between 65 and 74 years, 14 between 75 and 84 years and
6 >84 years (p = 0.764). Fourteen patients underwent sur-
gical procedures, one patient immediately and 13 due to
failure of the EGDS therapy. Of theses 14 cases, 4 were
<64 years, 2 between 65 and 74 years, 5 between 75 and
84 years, and 3 >84 years (p = 0.687). None of them pre-
sented with bleeding after the operation.
Seven patients out of 98 died (7.1% mortality). Two of
them were between 75 and 84 years and 5 >84 years.
There were no deaths among the youngest (p = 0.000)
patients. The number of deaths among ASA1, ASA2, ASA3,
and ASA4 classes (p = 0.002) were respectively 0, 4, 0 and
3. None of the 36 patients submitted only to medical ther-
apy died; 4 of the 47 (8.5%) patients submitted to endo-
scopic and medical therapy died; 3 of the 14 (21.4%)
patients operated died (p = 0.034). Three patients died
after the first haemostasis, 3 after the second and 1 after
the fourth. There were no deaths after medical therapy, 2
deaths from hemorrhage and 2 from non-correlated
pathologies after endoscopic and medical therapy. Surgi-
cal mortality was due in 1 case to hemorrhagic shock and
in 2 cases to surgical complications.
Complications were present in 2 patients <65 years, none
between 65 and 74 years, one patient between 75 and 84
years and 5 patients >84 years (p = 0.006). Patients treated
with medical therapy didn't experience any complication.
Among those 47 patients treated with endoscopic and
medical therapy there were 4 complications. There were 5
complications among those 14 who underwent surgery (p
= 0.001). There were 3 mortal hemorrhagic bleedings, 5
mortal cardiac complications and 2 intra-abdominal
abscesses.
At logistic regression the age, the ASA score and the type
of treatment had resulted correlated to mortality. The
same variables had resulted also correlated to morbidity.
Finally, the ulcer's position, the number of transfusions
and the number of EGDSs don't seem to have conditioned
the results.
Conclusion
The evaluation of the treatment outcome in our series of
patients suggests that endoscopic haemostasis and medi-
cal treatment should be the first therapeutic option in
ulcer cases with active bleeding. In the event of re-bleed-
ing, repeated endoscopic haemostasis is indicated. The
need for surgery is limited among cases where haemosta-
sis can't be performed due to the position of the ulcer or
the type of bleeding. In our experience, repeating the
endoscopic therapy has not increased the mortality risk
for the patient. In fact, deaths are more frequent after the
first and the second haemostasis. In the majority of cases
the resolution of the haemorrhage was achieved with the
first or second endoscopic haemostasis. Successive hae-
mostasis had a lower probability to resolve the bleeding
after the second re-bleeding. In the elderly and in the
patients with elevated surgical risk, the decision to extend
endoscopic treatment should be made on the basis of the
endoscopic findings and the patient's general condition.
In the last years besides the success of angiographic
embolization in the containment of massive haemor-
rhage must also be taken into account. The trans-catheter
arterial embolization is also an effective and safe treat-
ment in patients with duodenal ulcers re-bleeding after
therapeutic endoscopy or surgery.Page 2 of 2
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